Loading video...

Video Failed to Load

Go Home

Wizard Pathologists #2! (Hairy Cell Potter and the Slide Box of Secrets) MountSinai Pathology #pathology #pathologists

11,178 views • 1 year ago •via X (Twitter)

4 Comments

Nathan McGrath's profile picture
Nathan McGrath1 year ago

@MountSinai_Path That’s some serious buy in from the whole department 😂 love it

Nilüfer Kadıoğlu's profile picture
Nilüfer Kadıoğlu1 year ago

@MountSinai_Path Hilarious🤣

Aswathy Menon Ananthvikas's profile picture
Aswathy Menon Ananthvikas1 year ago

@MountSinai_Path Hilarious 😂😂

Behnas Malek F.Z's profile picture
Behnas Malek F.Z1 year ago

@MountSinai_Path This is so cool

Related Videos

⚡️📣👇Tremendously excited to share our new Cell article, where we develop TriPath, a method for analyzing 3D pathology samples using weakly supervised AI. Article: TriPath enables 3D computational pathology via 3D multiple instance learning allowing AI models to capture intricate morphological details from pathology volumes. Code: Blog post: Tested on two different imaging modalities, and patient cohorts from two institutions. Our superstar Andrew H. Song put in a monumental effort of leading the study, in a fantastic collaboration with Jonathan Liu at University of Washington . Interesting aspects: - Utilizing the whole tissue volume and leveraging 3D deep learning enable superior risk prediction performance compared to 2D deep learning baselines based on a few sampled tissue sections that emulate standard clinical practice. This indicates TriPath can harness additional information provided by 3D tissue morphology. - The performance is also superior to clinical baselines from a reader study that involved six expert pathologists. - The morphologically heterogeneous tissue volume could lead to opposing patient-level outcome predictions, dependent on which portion of the tissue volume is used. This concurs with current clinical literature warning that tissue sampling bias can lead to misdiagnosis. Some limitations: - While the 3D pathology cohort size is unprecedented, it is smaller than typical 2D pathology cohorts. Further large-scale studies will be required for validation. Nevertheless, we believe that this study will initiate a positive cycle, encouraging academic institutions and pharmaceutical companies to contribute large banks of human tissue blocks with paired clinical outcomes, thus speeding up advancements in 3D computational pathology. Concluding insights: We believe that 3D pathology is just around the corner - It has the huge potential to not only augment/improve the current clinical practice centered around 2D examination of human tissue, but also help reveal novel biomarkers for prognosis and therapeutic response.. Harvard Medical School Harvard Data Science Initiative Mass General Brigham Broad Institute

Faisal Mahmood

65,576 views • 2 years ago